Biotechnology continues to drive advances in medicine, from gene therapies to mRNA-based vaccines. For investors or traders seeking insight into this sector, market capitalisation remains a key measure.
Below are the world’s largest publicly listed biotechnology companies – defined as firms that derive more than half of their revenue from biotechnological processes – ranked by market capitalisation. Figures are calculated using each company’s latest closing share price and the fully diluted number of outstanding shares, as of 17 April 2026.
Our rankings below show the top biotechnology shares worldwide by market capitalisation, calculated as of 17 April 2026. Each company’s market capitalisation is presented in USD, together with its latest share price and main country of listing.
| Rank | Company | Market cap (USD) | Share price (USD) | Country |
|---|---|---|---|---|
| 1 | Eli Lilly | $828.3bn | $925.48 | United States |
| 2 | Johnson & Johnson | $566.8bn | $235.20 | United States |
| 3 | AbbVie | $373.5bn | $211.14 | United States |
| 4 | Roche | $337.5bn | $424.18 | Switzerland |
| 5 | AstraZeneca | $317bn | $204.47 | United Kingdom |
| 6 | Novartis | $292.8bn | $151.70 | Switzerland |
| 7 | Merck | $289.8bn | $117.20 | United States |
| 8 | Thermo Fisher Scientific | $196.1bn | $527.82 | United States |
| 9 | Amgen | $190.9bn | $354.12 | United States |
| 10 | Novo Nordisk | $182.3bn | $40.94 | Denmark |
Biotechnology is a broad scientific field that uses living organisms, cells and biological systems to develop products and processes, mainly in medicine, agriculture and industrial applications. In pharmaceuticals, biotech companies develop therapies using techniques such as recombinant DNA, monoclonal antibodies, gene editing (CRISPR), mRNA technology, and cell and gene therapy (Investing News Network, 23 December 2025). Unlike traditional pharmaceutical companies, which have historically relied more on chemical synthesis, biotech companies focus on biologically derived products, although the distinction is now less clear as large pharmaceutical groups acquire biotech pipelines (BioPharma Dive, 29 January 2026).
A company's market capitalisation is calculated by multiplying its current share price by the total number of outstanding shares. For large-cap biotech and pharma firms, this figure is often quoted on a fully diluted basis, so it includes all shares that could potentially exist, including those underlying stock options, convertible bonds and employee share schemes – calculated as:
Market cap is widely used as a measure of a company's size and investor-perceived value, though it reflects sentiment and expectations as well as fundamental performance. A single clinical trial result or regulatory decision can shift a biotech company's market cap by tens of billions of dollars within hours – as illustrated when Novo Nordisk's first CagriSema Phase III disappointment wiped approximately $125 billion from its market capitalisation in a single session (Reuters, 20 December 2024).
The dominance of biotech-adjacent companies in market cap rankings reflects the high commercial value of patented biological medicines. GLP-1 receptor agonists for obesity and diabetes, led by Eli Lilly's tirzepatide (Mounjaro/Zepbound) and Novo Nordisk's semaglutide (Ozempic/Wegovy), were a major commercial theme in the mid-2020s: combined Mounjaro and Zepbound sales reached $36.5 billion in FY2025, representing 56% of Eli Lilly's total revenue and driving a 45% year-on-year increase in the company's overall revenues (Fierce Pharma, 4 February 2026). Tirzepatide is projected to generate more than $45 billion in global sales in 2026, which would make it the world's top-selling drug (AInvest, 27 January 2026). Oncology remains the largest therapeutic category by pipeline volume, with Merck's Keytruda recording sales of $31.7 billion in 2025 – approximately 49% of Merck's total revenue – up 7% year-on-year, and AstraZeneca's oncology segment generating $25.6 billion in FY2025, up 17%, led by Tagrisso and Enhertu (Yahoo Finance / Zacks, 3 March 2026; Intellectia AI, 18 April 2026). Immunology blockbusters, notably AbbVie's Rinvoq and Skyrizi – which posted sales of $2.3 billion and $5.01 billion respectively in Q4 2025 alone, growing 29.5% and 32.5% year-on-year – illustrate how next-generation biologics are helping sustain large-cap valuations through the patent cliff cycle, with AbbVie projecting combined Skyrizi and Rinvoq revenues exceeding $31 billion by 2027 (Yahoo Finance, 4 February 2026).
Regulatory milestones are among the most important value catalysts for biotech companies. Approvals from the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) unlock the commercial revenue potential of drug candidates that may have taken a decade or more, and hundreds of millions of dollars, to develop (Investing News Network, 23 December 2025). A Phase III trial failure can erase 30–50% of a mid-cap biotech company's value overnight, while an unexpected approval can trigger the opposite effect. Novo Nordisk's steep market cap decline through late 2024 and into 2026 illustrates this dynamic: shares fell more than 26% after the Phase III REDEFINE 1 trial results in December 2024 missed the original 25% weight-loss target, wiping approximately $125 billion from its market value (Reuters, 20 December 2024), with a further 15% single-day decline in February 2026 after CagriSema failed to demonstrate non-inferiority against Lilly's tirzepatide in the head-to-head REDEFINE 4 trial, leaving the stock down approximately 36% over the prior year (Yahoo Finance, 23 February 2026; Yahoo Finance / Zacks, 3 February 2026).
The information on this page is based on data from public company disclosures, industry reports and market-data providers. It is provided for informational purposes only and does not constitute investment advice or a recommendation to trade. While believed to be accurate on the stated date, figures may change without notice.
Biotech CFD trading involves speculating on the price movements of biotechnology shares using contracts for difference (CFDs), without owning the underlying assets. Traders gain exposure to biotech developments – from gene editing to personalised medicine – while managing risk with tools such as stop-loss and take-profit orders. Adjustments may also be applied for dividends and other corporate actions.
Analysing a company’s pipeline, recent regulatory approvals (for example, FDA, EMA or PMDA) and financial position can provide useful context. Market sentiment around therapies, partnerships and trial milestones is also important. When trading CFDs, factors such as liquidity, trading hours, margin requirements and available leverage should be considered.
Biotech shares can be volatile around trial results, regulatory decisions or takeover speculation. Sudden price movements may increase both gains and losses, while binary events (such as trial failures) can result in significant declines. Risk-management tools and appropriate position sizing are essential, and traders should remain aware of ongoing sector developments.
Day traders may focus on earnings releases or clinical data announcements. Swing traders could hold positions around regulatory approvals, while longer-term traders might follow broader industry catalysts. It is important to note that holding CFDs overnight can incur financing charges.
A demo account can help beginners practise without risking real capital. It is useful to follow biotech-specific news – including clinical trial phases and regulatory updates – and to study basic chart patterns. Setting stop-loss levels and using leverage cautiously can help manage exposure in this highly volatile sector.
Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.
Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.
Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️
I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.
Love the TV integration. Makes traders life smooth and comfortable.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!
This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one
User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.
Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.
Why choose Capital.com? Our numbers speak for themselves
Capital.com Group
Ratings and Reviews
Ratings and Reviews